oncology APISintaho Pharmaceutical Ltd was established in the year of 2016 and headquartered in Chongqing China, with a grand vison of being the most trusted partner to pharmaceutical companies worldwide. We have a clear focus on developing and manufacturing highly potent and cytotoxic Active Pharmaceutical Ingredients (APIs) and CDMO services.
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Tirbanibulin is a potent topical kinase inhibitor developed for dermatological treatments. Its core synthesis involves specific chemical pathways to ensure high purity. The compound is defined by the molecular formula <strong>C21H25N7O4S</strong> and carries CAS No. <strong>1968077-88-8</strong>.</p>
<h3>Application</h3>
<ul>
<li>Primary treatment of actinic keratosis on the face or scalp.</li>
<li>Management of superficial skin lesions requiring rapid clearance.</li>
<li>Dermatological research into selective inhibition of Lck, Fyn, and Src kinases.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly for topical use only; avoid contact with eyes and mucous membranes. Store in a cool, dry place protected from light at controlled room temperature (20°C to 25°C). Do not exceed prescribed duration to prevent severe local reactions.</p>